We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Mycophenolate vs Azathioprin in Autoimmune Hepatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00687180
Recruitment Status : Completed
First Posted : May 30, 2008
Last Update Posted : May 30, 2008
Information provided by:

Study Description
Brief Summary:
A study with 20 de novo patients with autoimmune hepatitis, 10 receiving azathioprin and 10 receiving mycophenolat mofetil.

Condition or disease Intervention/treatment Phase
Autoimmune Hepatitis Drug: Treatment with mycophenolat mofetil Drug: Treatment with azathioprin Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: I
Drug: Treatment with mycophenolat mofetil
Active Comparator: II Drug: Treatment with azathioprin

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • De novo autoimmune hepatitis
  • Consent

Exclusion Criteria:

  • age below 18
  • pregnancy
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00687180

Rigshospitalet, Dept. of Hepatology A-2121
Copenhagen, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
More Information

Responsible Party: Bent Hansen, Chief of Dept. of Hepatology A-2121, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT00687180     History of Changes
Other Study ID Numbers: MMF vs Imurel
First Posted: May 30, 2008    Key Record Dates
Last Update Posted: May 30, 2008
Last Verified: May 2008

Keywords provided by Rigshospitalet, Denmark:
Prednisolone dosage

Additional relevant MeSH terms:
Hepatitis, Autoimmune
Liver Diseases
Digestive System Diseases
Hepatitis, Chronic
Autoimmune Diseases
Immune System Diseases